Pfizer’s Oral COVID-19 Pill Paxlovid Tops Merck’s Molnupiravir

 
• By Joseph Haas

Pfizer reported its protease inhibitor Paxlovid showed an 89% risk reduction for hospitalization and death compared to placebo in interim results of a Phase II/III trial. The pharma now is seeking a quick EUA in the US.

COVID-19 red cells on white
Pfizer's oral antiviral sharply reduces hospitalization/mortality risk in trial

More from COVID-19

More from Scrip